Noopept

Overview

Noopept is the common name for a synthetic compound also known by the code GVS-111 and the international name omberacetam. Chemically it is a proline-containing dipeptide, meaning it is built from a short two-amino-acid backbone with additional modifications. Although it is frequently grouped with the racetam family of nootropics because of similar intended effects, its structure is distinct from classic racetams.

Noopept was developed in Russia, where it is marketed as a prescription medication for cognitive and memory-related complaints. Its regulatory standing varies dramatically by country, and in many Western markets it occupies a legal gray area, being neither an approved drug nor clearly classified.

It is widely sold online as a nootropic supplement or research chemical. Consumers should be aware that this widespread availability does not reflect a robust body of high-quality clinical evidence. Much of the popular enthusiasm around noopept rests on early laboratory work and user reports rather than large, rigorous human trials.

How it works

The proposed mechanisms of noopept are several and remain incompletely established. The most frequently cited hypothesis is that noopept increases the expression of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). These signaling proteins support the survival, growth, and plasticity of neurons, which is the basis for claims that noopept supports learning and memory.

Other proposed actions include modulation of glutamate signaling and antioxidant or neuroprotective effects observed in animal models of injury and stress. Some researchers have suggested that a metabolite of noopept resembles an endogenous peptide involved in memory processes, though this remains a hypothesis rather than settled fact.

As with many nootropics, it is important to distinguish mechanism from outcome. Demonstrating that a compound raises BDNF in rodents or protects cells in a dish does not establish that it improves cognition in healthy humans. The mechanistic story for noopept is biologically interesting but should be read as a set of plausible explanations rather than confirmed pathways underlying a proven clinical effect.

Research & evidence

The research base for noopept is concentrated heavily in Russian-language studies and preclinical experiments. Animal models have explored its effects on memory, learning, neuroprotection following induced injury, and anxiety-like behavior, and these studies form the foundation of most claims made about the compound.

Human clinical data exist but are limited in scope and have been conducted largely outside the framework of large international trials. Some studies have examined noopept in people with mild cognitive impairment or post-injury cognitive complaints, reporting improvements, but these trials are generally small, and the broader scientific community has not independently validated them at scale.

What is largely missing is high-quality evidence in healthy individuals using noopept for cognitive enhancement, which is its most common real-world use. There is little rigorous support for the idea that noopept reliably improves memory or focus in people without a diagnosed condition. The honest position is that noopept is an under-studied compound by Western regulatory standards, and confident claims about its benefits outpace the strength of the available data.

Safety & legal status

Noopept's long-term safety in humans has not been thoroughly characterized through large, controlled trials. In the studies that exist it has often been described as relatively well tolerated, but the absence of extensive safety data means that rare or long-term risks cannot be ruled out. Reported effects in various settings include headache, irritability, and sleep disturbance, and interactions with other substances are poorly studied.

Legally, noopept is a prescription medicine in Russia and some neighboring countries. In the United States it is not approved by the FDA for any medical use and is not authorized as a dietary supplement, yet it is commonly sold online, placing it in an enforcement and regulatory gray area. In several other countries, including parts of Europe and Australia, it is more tightly controlled.

Because products sold as noopept are not regulated for pharmaceutical quality, purity and accurate labeling cannot be assumed. Anyone considering it should recognize that they would be using an unapproved compound with limited safety data, and discussion with a healthcare professional is strongly advisable.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Ostroumova RU, Gudasheva TA, Zaplina AP, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008. Peer-reviewed study
2. Ostrovskaia RU, Vakhitova IuV, Salimgareeva MKh, et al. On the mechanism of noopept action: stress-induced kinases and neurotrophin expression. Eksp Klin Farmakol. 2010. Peer-reviewed study
3. Pelsman A, Hoyo-Vadillo C, Gudasheva TA, et al. GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int J Dev Neurosci. 2003. Peer-reviewed study
4. Araj SK, Szeleszczuk Ł, Gubica T, et al. Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) - An active pharmaceutical ingredient with nootropic activity. J Pharm Biomed Anal. 2025. Peer-reviewed study
5. Gürbüz P, Düzova H, Yildiz A, et al. Effects of noopept on cognitive functions and pubertal process in rats with diabetes. Life Sci. 2019. Peer-reviewed study
6. Gurbuz P, Duzova H, Taslidere AC, et al. Effects of noopept on ocular, pancreatic and renal histopathology in streptozotocin induced prepubertal diabetic rats. Biotech Histochem. 2023. Peer-reviewed study